Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

BACKGROUND: Effects of roflumilast on lung function, symptoms, acute exacerbation and adverse events in patients with chronic obstructive pulmonary disease (COPD) are controversial. We aimed to further clarify the efficacy and safety of roflumilast in treatment of moderate-to-severe COPD. METHODS: F...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jian, Wang, Ke, Liu, Dan, Liang, Bin-Miao, Liu, Chun-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756424/
https://www.ncbi.nlm.nih.gov/pubmed/26887407
http://dx.doi.org/10.1186/s12931-016-0330-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756424/
https://www.ncbi.nlm.nih.gov/pubmed/26887407
http://dx.doi.org/10.1186/s12931-016-0330-y

Ejemplares similares